Scientist I/II, Early Discovery Biology at Abata Therapeutics

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years), Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

PhD in Biology, Cell Biology, or relevant discipline with 0-2 years of industry experience
OR B.S. or M.S. with 6+ years of industry experience and a strong scientific track record
Proven track record of developing novel cell-based assays and engineering cell lines
Experience in cellular readouts of protein activity (e.g., transcriptional/translational reporters, NanoBit/BRET, qPCR, HTRF, flow)

Responsibilities

Lead efforts to design and develop cell-based assays to functionally characterize small molecule binders arising from our RAPID platform
Perform structure activity relationship (SAR) assays to drive medicinal chemistry
Become a subject matter expert on target biology and disease area
Generate and characterize cell lines for RAPID platform screening
Critically evaluate potential new targets for technical feasibility and disease relevance
Work collaboratively with Discovery Technology colleagues across protein biochemistry and structural biology
Leverage drug discovery experience to impact Jnana’s pipeline and strategy
Deliver regular presentations of your data to colleagues and leadership

Skills

Molecular Biology

Cell Biology

Cell-based Assays

Cell Line Engineering

Small Molecule Validation

Assay Development

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free